Lawmakers and the Obama administration are ratcheting up efforts to target pharmaceutical companies over high-priced drugs, a sign that legislators are trying to bridge partisan differences to tackle a key driver of rising health care costs.
Some specialty drugs can now run $100,000 or more a year, and the issue has been amplified by several high-profile cases in which makers boosted prices dramatically and rapidly.
Read Full Article »